| A B RIEF INTRODUC TI ON TO THE HEMOG LOB INOPATHIE S
The major hemoglobin in a healthy adult is HbA (α 2 β 2 ), with small amounts of HbA 2 , (α 2 δ 2, <2.5%-3.0%) and HbF (α 2 γ 2 , 1%-2%). The thalassemias are grouped according to which globin chain(s) have reduced synthesis, the 2 main categories being α-thalassemias and the β-thalassemias. The most common and clinically relevant hemoglobin variants, all of which affect the β-globin chain, include Hb S, Hb C, Hb E, Hb D-Punjab, and Hb O-Arab. The severest hemoglobinopathies for which prenatal and preimplantation diagnoses could be considered are summarized in Table 2 .
The molecular genetics of the hemoglobinopathies is extremely complex. 5 Two, almost identical, α-globin genes (HBA1 and HBA2), which encode the α-globin polypeptide chains, are located on chromosome 16p13.3, close to several other highly homologous genes (5′ HBZ, HBA2, and HBA1 3′). A single β-globin gene (HBB) encoding the β-globin chains is located on chromosome 11p15.5 along with other globin genes which together form the so-called β-globin gene cluster: 5′ HBE, HBG2, HBG1, HBD, and HBB 3′.
Nearly 1600 variations within and nearby the various globin genes have been described 13, 14 Details on the spectrum of all mutations are thoroughly described elsewhere. 5, 13, 14 Data on the phenotype and epidemiology of hemoglobinopathies are found in Table 2 .
| CHAR AC TERIZING COUPLE S AT RIS K FOR TR AN S MIT TING HEMOG LOB INOPATHIE S
A prerequisite for prenatal or preimplantation diagnosis is the timely identification of carrier couples. Current best practice recommends that screening to identify carriers be carried out using hematological and biochemical methods. 10, 11 Hemoglobinopathy screening requires a wide range of tests, and thus, only laboratories with appropriate infrastructure, and staffed by professionals with expertise, can support the interpretation of hematological findings. 3, 4, 10, 11 Diagnosis based on hematological parameters is presumptive for most cases and not definitive. To achieve the latter, molecular (DNA) analysis is required.
In each population group where the hemoglobinopathies are/ were traditionally endemic, there are up to around 20 different mutations each for α-thalassemia and β-thalassemia, along with perhaps 1 or 2 clinically significant hemoglobin variants. Thus, the molecular characterization of genotypes in carriers generally requires a wide range of methodologies, the majority of which are based on the polymerase chain reaction (PCR). 4, 10 The mutation detection methods that have most commonly been adopted for genotyping hemoglobinopathies are summarized in Table 3 and are selected according to the spectrum of mutations expected, the sample throughput, the laboratory infrastructure, and the available expertise and budget. Ideally, generic methods such as direct sequencing (for any nucleotide variant) and multiplex ligation-dependent probe amplification, MLPA (for larger deletions or duplications), are preferable and are particularly relevant when supporting genotyping services in multi-ethnic societies that have resulted from global migration. 4, 10 More recently, methods using specially targeted massively parallel sequencing, MPS (also known as next-generation sequencing, NGS) of the globin genes, and their clusters have been described for carrier detection and genotyping in subjects with hemoglobinopathies. 15, 16 However, MPS/NGS-based methods for hemoglobinopathy carrier-screening and genotyping require further validation, and a reduction in cost, before they can be used for routine clinical applications.
| CONVENTIONAL PRENATAL DIAG NOS IS FOR HEMOG LOB INOPATHIE S
The aim of PND is to deliver an accurate result as early in pregnancy completed within a few working days and reported to the couples with support of genetic counseling. 10 Although conventional PND is a well-established and accurate procedure, the main disadvantages include the need for invasive biopsy of fetal material, which carries a small risk (1%-2%) of pregnancy loss, and the potential requirement to terminate affected pregnancies, the latter associated with widely debated ethical and social implications. 
TA B L E 1 Comparison between current and emerging prenatal and preimplantation genetic diagnostic procedures
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| PREIMPL ANTATI ON D IAG NOS IS FOR MONOG ENIC DIS E A S E S (P G T-M)-AN INTRODUC TI ON
In contrast to conventional PND, PGT-M overcomes the need to terminate affected ongoing pregnancies. The first clinical application of preimplantation genetic diagnosis (PGT-M) was reported in 1990, and the first PGT-M cycles for β-thalassemia were reported in 1998. Although, PGT-M precludes pregnancy termination, the major disadvantages include that the couple requires ART even if they are fertile, that pregnancy initiation following embryo transfer is not certain, and that in many countries, the couples bear the high cost of the procedure.
Overall, PGT-M is a challenging procedure with many stages summarized in Figure 1 . For the genetic analysis, there are 3 developmental stages at which cells suitable for analysis can be biopsied.
These include polar bodies (PBs) from the oocyte/ zygote stage, blastomeres from cleavage-stage embryos, or trophectoderm cells from blastocysts. For each PGT-M case, the best option is selected according to the genetic analysis required, the number and quality of zygotes/embryos available, and the preferred timing of embryo transfer (which can vary from day 3 to day 6, or even following cryopreservation). Thus, PGT-M requires input not only from laboratory geneticists who are expert in diagnosis of minute quantities of DNA, but also gynecologists expert in ART and embryologists expert in gamete and embryo manipulations.
12,17,18
The most challenging step in PGT-M remains that of genotyping,
as it is based on the analysis of extremely limited amounts of genetic material. Additionally, if the couple prefers the transfer of fresh embryo(s) in their PGT-M cycle, the genetic analysis has to be com- To increase accuracy in PGT-M, more robust protocols were adopted to include the additional analysis of several polymorphic genetic loci linked to the normal or variant allele of the prospective parents, the so-called multiplex-PCR protocols. As for PND, STRs are the category most commonly used in PGT-M, but it is recommended that they be located within 1 megabase of the diseasecausing mutation site to minimize occurrence of recombination and therefore possibility of misdiagnosis. 12 An alternative category of polymorphic markers used in PGT-M is single nucleotide polymorphisms (SNPs). Although SNPs are found more densely across the genome than STRs, they are typically only biallelic, and thus, many more loci need to be analyzed to deduce linkage. SNPs are utilized in methods such as SNP microarrays or TaqMan genotyping probes, which however, require more specialized equipment minimizing their wider adoption to date. 19, 20 The most important application of SNPs is NGS technology, which, as for carrier screening and PND, is likely to become a feasible and valuable option for PGT-M in the foreseeable future.
21-23
The 3 genotyping strategies that have been most validated and commonly used for PGT-M include the following: (i) multiplex-PCR protocols involving the simultaneous amplification of many genetic loci directly in the biopsied zygote/embryo sample; (ii) strategies that apply whole genome amplification (WGA) directly on the biopsied zygote/embryo sample, followed by nested-PCR analysis of many STRs; (iii) WGA directly on the biopsied zygote/embryo sample, followed by hybridization to SNP microarrays.
17-20,24
| PREIMPL ANTATI ON D IAG NOS IS FOR HEMOG LOB INOPATHIE S
PGT-M for hemoglobinopathies represents one of the most common applications for monogenic diseases according to the annual data collections published by the European Society of Human Reproduction and Embryology, ESHRE.
25
The first PGT-M cycles for β-thalassemia, reported in 1998, were based on analysis of PBs using nested PCR with restriction enzyme analysis of the disease-causing mutations, along with linked STRs. 
27,28
With respect to PGT-M for the severe forms of α-thalassemia, the need to detect large deletions (the most common defect underlying
TA B L E 3 Methods for DNA analysis of globin gene variants
Methods
Mutation detection categories
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Reverse dot blot hybridization (RDB) 24 
| PREIMPL ANTATI ON D IAG NOS IS FOR H UMAN LEUKO C Y TE ANTI G EN (HL A ) TE S TING (P G D -HL A )
While the selection of a histocompatible embryo to facilitate an HSCT in a sibling with a severe disorder was ethically controversial when first applied, it has become an accepted procedure in many societies, although it is offered by a limited number of centers worldwide. For families who fail to find a compatible donor within the family or one from a donor bank, PGD-HLA may be the only option.
Preimplantation genetic diagnosis for human leukocyte antigen testing has the combined purpose to establish a pregnancy with an embryo HLA compatible with the affected sibling and at the same time unaffected for the familial disorder. 8 The first PGD-HLA matching case was reported in 2001 for Fanconi anemia and since then the number of reported cases has increased every year. According to data from ESHRE, the most common indication to date for HLA matching is β-thalassemia and sickle-cell syndromes.
25
In the context of PGD-HLA, reliable genotyping of the HLA locus is technically challenging. It has to address the large size (>3.6 Mb)
and highly polymorphic nature of the HLA locus, and the likelihood of recombination. The first cases reported for HLA typing involved direct genotyping of specific single nucleotide variants in the HLA genes. However, this cumbersome family-specific approach has been replaced by multiplex haplotyping across the HLA locus using STRs for linkage analysis. 29 To exclude the familial hemoglobinopathy, the HLA multiplex is also optimized to include also the multiplex-PCR assay for the HBB locus. Guidelines recommend the minimum number of STR markers to use, as well as which of the HLA regions should be covered. 12 The optimization of a PGD-HLA protocol may span from a few weeks to several months, depending on the informativity of STR markers in the family and the ability to co-amplify suitable STRs in one multiplex-PCR protocol. 8 Even if all technical aspects for the genetic diagnosis are resolved, the ultimate success, that is, the birth of an unaffected histocompatible baby is limited by several factors beyond the control of the laboratory. Genetic probability predicts that only 18.8% of all embryos fertilized in any cycle will be suitable for transfer (the likelihood that 2 siblings are HLA matched is 25%, and only 75%
of matched embryos will be unaffected for the hemoglobinopathy). In the light that implantation, pregnancy, and delivery rates in
ART are approximately 30% on average, the overall success rate for
PGD-HLA matching, that is, the birth of an unaffected histocompatible baby, rarely surpasses about 10%-15% for any cycle initiated. 8 Thus couples (families) should be thoroughly counseled before embarking on a PGD-HLA procedure. Overall, HLA typing with PGD is not an easy option, although it is most valuable when it succeeds in curing an affected child. 30 
| NONINVA S IVE PRENATAL DIAG NOS IS FOR HEMOG LOB INOPATHIE S-LOOKING TO THE FUTURE
The discovery of free-fetal nucleic acids (DNA and RNA) in the circulation of a pregnant mother stimulated intensive research efforts toward developing approaches for "noninvasive" prenatal Sophia's Children's Hospital, Athens 11527, Greece.
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